The ruling is a major setback for Amgen, which had sought to protect its blockbuster drug from generic competition. Repatha, which is used to treat high cholesterol, generated $1.3 billion in sales in 2019.
rnrnThe Supreme Court’s decision is a victory for Sanofi, which had argued that Amgen’s patents were invalid because they did not provide enough information to enable a generic version of the drug to be made.
rnrnThe ruling is also a win for generic drugmakers, who will now be able to produce generic versions of Repatha without fear of legal action from Amgen. This could lead to lower prices for consumers and increased competition in the market.